Company Profile

Disruptive Pharma AB (publ), formerly Guard Therapeutics International AB (publ), is a Sweden-based company, which is active within the healthcare sector. The Company conducts development and commercialization of treatment and diagnostics based on the alpha-1-microglobulin (A1M) protein. The protein serves as a radical inhibitor, an antioxidant, a protector against free hemoglobin and a tissue repairer. A1M is a candidate for different therapeutic and diagnostic uses, such as alleviation of autoimmune diseases and stroke treatment. The Company works with the protein and conducts research at the Biomedical Center in Lund University, Sweden. The Company develops a drug for intravenous treatment of preeclampsia, a condition that can occur during pregnancy and can contribute to premature deliveries.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
30/10/26	SEK 1.134	+2.53%	33,795
29/10/26	SEK 1.106	-0.54%	2,640
28/10/26	SEK 1.112	-10.32%	59,610
27/10/26	SEK 1.240	+13.76%	12,268
26/10/26	SEK 1.090	+3.61%	6,393

Delayed Quote Nasdaq Stockholm

More quotes

Delayed Nasdaq Stockholm 16:30:00 30/10/2026 +04			5-day change	1st Jan Change
1.134 ^SEK	+2.53%		+7.79%	-22.86%

09-07	Strand Småbolagsfond rose 3.58 percent in August, strong trend in the stock market	FW
07-27	Disruptive Pharma Holding Ab completed the acquisition of Guard Therapeutics International AB (OM:GUARD) in a reverse merger transaction in a transaction.	CI

Markets		Quality
Nasdaq Stockholm	DPHA	Delayed
Deutsche Boerse AG	5LH0	Delayed
Boerse Muenchen	5LH0	Real-time

09-07	Strand Småbolagsfond rose 3.58 percent in August, strong trend in the stock market	FW
07-27	Disruptive Pharma Holding Ab completed the acquisition of Guard Therapeutics International AB (OM:GUARD) in a reverse merger transaction in a transaction.	CI
07-17	Guard Therapeutics Gets Conditional Approval For Continued Listing	RE
07-17	Guard Therapeutics Secures Conditional Nasdaq Listing Approval Ahead of Disruptive Pharma Takeover	MT
06-12	Guard Therapeutics Initiates Divestment of GTX Platform	MT
06-11	Guard Therapeutics to Acquire Disruptive Pharma in Reverse Takeover	MT
06-11	Guard Therapeutics announces reverse takeover and planned name change	FW
06-10	Disruptive Pharma Holding Ab entered into a conditional agreement to acquire Guard Therapeutics International AB (OM:GUARD) in a reverse merger transaction in a transaction valued at SEK 61 million.	CI
05-11	Guard Therapeutics loss before and after tax SEK 6.4 mln	RE
05-11	Guard Therapeutics International AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-13	Seven stocks hit new 52-week lows on the Stockholm Stock Exchange so far today	FW
04-10	Three stocks hit new 52-week lows on the Stockholm Stock Exchange so far today	FW
03-31	Guard Therapeutics updates on strategic review	RE

26/10/25	Guard Therapeutics Announces Top-Line Results from Phase 2b POINTER Study	CI
11/09/25	Redeye Initiates Coverage of Guard Therapeutics with Target Value of SEK 43	FW

Disruptive Pharma AB Stock

Stocks

DPHA

SE0021181559

Biotechnology & Medical Research

Chart: Disruptive Pharma AB

Latest news: Disruptive Pharma AB

Last Transcript: Disruptive Pharma AB

Analysts' recommendations: Disruptive Pharma AB

Press Releases: Disruptive Pharma AB

News in other languages: Disruptive Pharma AB

Quotes and Performance

Price Extremes

Latest insider transactions

Other Biotechnology & Medical Research

Company Profile

Quotes

10-09	Beyond bioavailability: from formulation to viable drug product	PU
09-29	Disruptive Pharma : to attend CPHI Milan 2026	PU
09-22	Disruptive Pharma divests GTX platform and retains rights to future royalty and milestone revenues	AQ
09-16	Disruptive Pharma : Tobias Assander joins Disruptive Pharma as Manufacturing and Process Development Lead	PU
08-18	Disruptive Pharma to ring the opening bell at Nasdaq Stockholm	AQ

07/04/21	ERS Test AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG
07/04/21	ERS Test AG: Vorabbekanntmachung über die Veröffentlichung von Zahlungsberichten gemäß § 116 WpHG

1 day	+2.53%
1 week	+7.79%
Current month	-12.63%
1 month	-12.63%
3 months	-28.68%
6 months	+6.98%
Current year	-22.86%

1 week	1	1.29
1 month	1	1.29
Current year	0.88	2.35
1 year	0.88	2.35
3 years	0.88	46
5 years	0.88	74.5
10 years	0.88	2,590

Date	Insider	Type	Main position	Quantity	% Market Cap.
28/02/23	Tobias Larsson Agervald	Free	Chief Executive Officer	9,450,000	1.8784%
28/02/23	Karin Botha	Free	Chief Financial Officer	2,520,000	0.5009%
28/02/23	Peter Gilmour	Free		1,344,000	0.2672%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
DISRUPTIVE PHARMA AB	+2.53%	+7.79%	-30.85%	-96.49%	5M
WUXI APPTEC CO., LTD.	-0.62%	+0.50%	+33.92%	+60.07%	64.38B
ARGENX SE	+0.77%	+3.66%	+15.43%	+85.37%	56.16B
LONZA GROUP AG	+0.42%	+1.80%	+15.19%	+106.48%	54.16B
IQVIA HOLDINGS INC.	-3.22%	-4.98%	+22.62%	+49.83%	45.33B
BEONE MEDICINES AG	+0.45%	-1.21%	+21.04%	+99.91%	42.25B
REVOLUTION MEDICINES, INC.	-0.86%	+0.68%	+219.81%	+925.99%	40.78B
GENMAB A/S	+3.27%	+47.96%	+112.67%	+96.48%	33.8B
CELLTRION, INC.	+1.22%	-1.39%	+13.92%	+46.95%	32.25B
WUXI BIOLOGICS (CAYMAN) INC.	-1.29%	-1.72%	+21.00%	-6.85%	23.57B
Average	+0.27%	+4.41%	+44.47%	+136.78%	39.27B
Weighted average by Cap.	-0.04%	+3.64%	+49.67%	+161.16%